Deutsche Bank
IMUC

Deutsche Bank’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Deutsche Bank’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Hold
0
– – – 5323
2016
Q3 		– Hold
0
– – – 5580
2016
Q2 		– Hold
0
– – – 5623
2016
Q1 		– Hold
0
– – – 5623
2015
Q4 		– Sell
-63
Closed -$1.04K – 5646
2015
Q3 		$1K Sell
63
-9,128
-99% -$166K ﹤0.01% 5165
2015
Q2 		$173K Buy
9,191
+7,520
+450% +$145K ﹤0.01% 3961
2015
Q1 		$32K Buy
1,671
+569
+52% +$14.3K ﹤0.01% 4526
2014
Q4 		$32K Sell
1,102
-2,969
-73% -$85.4K ﹤0.01% 5357
2014
Q3 		$144K Buy
4,071
+250
+7% +$9.63K ﹤0.01% 4275
2014
Q2 		$170K Buy
3,821
+1,258
+49% +$60.7K ﹤0.01% 4236
2014
Q1 		$125K Buy
2,563
+2,560
+85,333% +$125K ﹤0.01% 4134
2013
Q4 		$0 Sell
3
-997
-100% -$94.4K ﹤0.01% 6146
2013
Q3 		$102K Sell
1,000
-2,367
-70% -$260K ﹤0.01% 4424
2013
Q2 		$261K Buy
+3,367
New +$322K ﹤0.01% 3644

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deutsche Bank's IMUC Position: Q4 2016 in Review

Deutsche Bank held its ImmunoCellular Therapeutics, Ltd. (IMUC) position steady in Q4 2016 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5323.

Deutsche Bank first reported a position in IMUC in Q2 2013 and has held it in 10 quarters since. The position peaked at $261K in Q2 2013. 16 funds tracked by Wall St. Rank hold IMUC as of Q4 2016.

  • Deutsche Bank held 0 shares of ImmunoCellular Therapeutics, Ltd. worth $0 as of Q4 2016.
  • Deutsche Bank left its ImmunoCellular Therapeutics, Ltd. share count unchanged in Q4 2016.
  • ImmunoCellular Therapeutics, Ltd. made up ﹤0.01% of Deutsche Bank's portfolio in Q4 2016, its #5323 holding.
  • Deutsche Bank first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and has held it in 10 quarters since.
  • Deutsche Bank's ImmunoCellular Therapeutics, Ltd. position peaked at $261K in Q2 2013.
  • 16 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2016.

Based on Deutsche Bank's 13F filing for Q4 2016, filed 14 Feb 2017.